Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion type Assertion NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_head.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion description "[The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_provenance.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion evidence source_evidence_literature NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_provenance.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion SIO_000772 17496311 NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_provenance.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion wasDerivedFrom befree-2016 NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_provenance.
- NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_assertion wasGeneratedBy ECO_0000203 NP609485.RALMwL4WTKlJd9JLnEerJY50XtlSdzE9O2cFHnq6x_rmM130_provenance.